Valuing Pharmaceutical Drug Innovations

Valuing Pharmaceutical Drug Innovations

We propose a methodology to estimate the market value of pharmaceutical drugs. Our approach combines an event study with a model of discounted cash flows and uses stock market responses to drug development announcements to infer the values. We estimate that, on average, a successful drug is valued a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Aryal, Gaurab, Ciliberto, Federico, Farmer, Leland E, Khmelnitskaya, Ekaterina
Format: Artikel
Sprache:eng
Schlagworte:
Quantitative Finance - Economics
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator Aryal, Gaurab
Ciliberto, Federico
Farmer, Leland E
Khmelnitskaya, Ekaterina
description We propose a methodology to estimate the market value of pharmaceutical drugs. Our approach combines an event study with a model of discounted cash flows and uses stock market responses to drug development announcements to infer the values. We estimate that, on average, a successful drug is valued at \$1.62 billion, and its value at the discovery stage is \$64.3 million, with substantial heterogeneity across major diseases. Leveraging these estimates, we also determine the average drug development costs at various stages. Furthermore, we explore applying our estimates to design policies that support drug development through drug buyouts and cost-sharing agreements.
doi_str_mv 10.48550/arxiv.2212.07384
format Article
fullrecord <record><control><sourceid>arxiv_GOX</sourceid><recordid>TN_cdi_arxiv_primary_2212_07384</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2212_07384</sourcerecordid><originalsourceid>FETCH-LOGICAL-a674-a2a089016bc9769d517772442fef7f584616e83b7555c47b053524e078b91fcf3</originalsourceid><addsrcrecordid>eNotzrtuwjAUgGEvDBXwAJ3IxpTUt-PjjIiWi4TUDog1OjE2WAqhMgTB2yMu07_9-hj7FLzQFoB_UbrGSyGlkAVHZfUHG2-o6WK7y_72lA7kfHeOjprsO3W7bNm2xwud47E9DVgvUHPyw3f7bD37WU8X-ep3vpxOVjkZ1DlJ4rbkwtSuRFNuQSCi1FoGHzCA1UYYb1WNAOA01hwUSO052roUwQXVZ6PX9imt_lM8ULpVD3H1FKs7ZuE5qg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Valuing Pharmaceutical Drug Innovations</title><source>arXiv.org</source><creator>Aryal, Gaurab ; Ciliberto, Federico ; Farmer, Leland E ; Khmelnitskaya, Ekaterina</creator><creatorcontrib>Aryal, Gaurab ; Ciliberto, Federico ; Farmer, Leland E ; Khmelnitskaya, Ekaterina</creatorcontrib><description>We propose a methodology to estimate the market value of pharmaceutical drugs. Our approach combines an event study with a model of discounted cash flows and uses stock market responses to drug development announcements to infer the values. We estimate that, on average, a successful drug is valued at \$1.62 billion, and its value at the discovery stage is \$64.3 million, with substantial heterogeneity across major diseases. Leveraging these estimates, we also determine the average drug development costs at various stages. Furthermore, we explore applying our estimates to design policies that support drug development through drug buyouts and cost-sharing agreements.</description><identifier>DOI: 10.48550/arxiv.2212.07384</identifier><language>eng</language><subject>Quantitative Finance - Economics</subject><creationdate>2022-12</creationdate><rights>http://creativecommons.org/licenses/by/4.0</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>228,230,776,881</link.rule.ids><linktorsrc>$$Uhttps://arxiv.org/abs/2212.07384$$EView_record_in_Cornell_University$$FView_record_in_$$GCornell_University$$Hfree_for_read</linktorsrc><backlink>$$Uhttps://doi.org/10.48550/arXiv.2212.07384$$DView paper in arXiv$$Hfree_for_read</backlink></links><search><creatorcontrib>Aryal, Gaurab</creatorcontrib><creatorcontrib>Ciliberto, Federico</creatorcontrib><creatorcontrib>Farmer, Leland E</creatorcontrib><creatorcontrib>Khmelnitskaya, Ekaterina</creatorcontrib><title>Valuing Pharmaceutical Drug Innovations</title><description>We propose a methodology to estimate the market value of pharmaceutical drugs. Our approach combines an event study with a model of discounted cash flows and uses stock market responses to drug development announcements to infer the values. We estimate that, on average, a successful drug is valued at \$1.62 billion, and its value at the discovery stage is \$64.3 million, with substantial heterogeneity across major diseases. Leveraging these estimates, we also determine the average drug development costs at various stages. Furthermore, we explore applying our estimates to design policies that support drug development through drug buyouts and cost-sharing agreements.</description><subject>Quantitative Finance - Economics</subject><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>GOX</sourceid><recordid>eNotzrtuwjAUgGEvDBXwAJ3IxpTUt-PjjIiWi4TUDog1OjE2WAqhMgTB2yMu07_9-hj7FLzQFoB_UbrGSyGlkAVHZfUHG2-o6WK7y_72lA7kfHeOjprsO3W7bNm2xwud47E9DVgvUHPyw3f7bD37WU8X-ep3vpxOVjkZ1DlJ4rbkwtSuRFNuQSCi1FoGHzCA1UYYb1WNAOA01hwUSO052roUwQXVZ6PX9imt_lM8ULpVD3H1FKs7ZuE5qg</recordid><startdate>20221214</startdate><enddate>20221214</enddate><creator>Aryal, Gaurab</creator><creator>Ciliberto, Federico</creator><creator>Farmer, Leland E</creator><creator>Khmelnitskaya, Ekaterina</creator><scope>ADEOX</scope><scope>GOX</scope></search><sort><creationdate>20221214</creationdate><title>Valuing Pharmaceutical Drug Innovations</title><author>Aryal, Gaurab ; Ciliberto, Federico ; Farmer, Leland E ; Khmelnitskaya, Ekaterina</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a674-a2a089016bc9769d517772442fef7f584616e83b7555c47b053524e078b91fcf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Quantitative Finance - Economics</topic><toplevel>online_resources</toplevel><creatorcontrib>Aryal, Gaurab</creatorcontrib><creatorcontrib>Ciliberto, Federico</creatorcontrib><creatorcontrib>Farmer, Leland E</creatorcontrib><creatorcontrib>Khmelnitskaya, Ekaterina</creatorcontrib><collection>arXiv Economics</collection><collection>arXiv.org</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Aryal, Gaurab</au><au>Ciliberto, Federico</au><au>Farmer, Leland E</au><au>Khmelnitskaya, Ekaterina</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Valuing Pharmaceutical Drug Innovations</atitle><date>2022-12-14</date><risdate>2022</risdate><abstract>We propose a methodology to estimate the market value of pharmaceutical drugs. Our approach combines an event study with a model of discounted cash flows and uses stock market responses to drug development announcements to infer the values. We estimate that, on average, a successful drug is valued at \$1.62 billion, and its value at the discovery stage is \$64.3 million, with substantial heterogeneity across major diseases. Leveraging these estimates, we also determine the average drug development costs at various stages. Furthermore, we explore applying our estimates to design policies that support drug development through drug buyouts and cost-sharing agreements.</abstract><doi>10.48550/arxiv.2212.07384</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier DOI: 10.48550/arxiv.2212.07384
ispartof
issn
language eng
recordid cdi_arxiv_primary_2212_07384
source arXiv.org
subjects Quantitative Finance - Economics
title Valuing Pharmaceutical Drug Innovations
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T10%3A51%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-arxiv_GOX&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Valuing%20Pharmaceutical%20Drug%20Innovations&rft.au=Aryal,%20Gaurab&rft.date=2022-12-14&rft_id=info:doi/10.48550/arxiv.2212.07384&rft_dat=%3Carxiv_GOX%3E2212_07384%3C/arxiv_GOX%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true